Gene editing: a brief regional analytical overview

European perspective

GMO technology was initially faced with fierce opposition in Europe in the 2000s because the continent places high importance on food quality and authenticity. Demonstrators assaulted test sites and branded goods as "frankenfoods." Only one strain of genetically modified wheat was ever produced in the EU due to the tight regulations (although dozens of crops are now authorised for imports, mostly for animal feed).

In Europe, attitudes toward gene editing are changing. Agriculture ministers from the EU's 27 member nations requested Brussels in September to expedite a review of GMO regulation. The European Commission indicated the following month that it would submit a proposal to reduce the regulation of some gene-editing technology in the second quarter.

European Union laws on genetically modified food have historically been rather rigorous, but the continent is gradually permitting newer varieties of modified maize and other agricultural products. Additionally, different nations in the European Union have different levels of GMO acceptability, with Spain and Portugal being more open to them than France and the Nordic people. Sweden is a significant exception, though. In this nation, the government has determined that the definition of a genetically modified organism (GMO) requires that an organism include foreign DNA for it to be considered a GMO. it is required in Europe for all food (including processed food) and feed that includes more than 0.9% of authorized GMOs.

The Swiss Council of States approved an extension to the national ban on the production of GM crops in December 2021, but they also introduced an exemption for gene editing technology. Plants that are developed via "gene-editing without the addition of foreign genetic material" would be exempt from the rule. The Parliament has received that amendment to the GM crop moratorium extension.
A joint proposal to remove gene-editing technology from an extension of the country's ban on the production of genetically modified crops has been approved by the Swiss Council of States. It should be possible to extend the ban on GM and gene-edited crops once more, this time till the end of 2025, provided that there is a strategy in place to segregate gene editing from GM crops during that time.

Latin America perspective

Latin America is a large territory with incredible biodiversity and an increasing population that must be fed. Even after the introduction of genetic engineering, the issue persists, with certain LATAM countries enacting prohibitions and limits. Now, scientific innovation is steering the region in a new direction. Farmers are collaborating with scientists to develop new crop varieties using gene editing techniques such as CRISPR-CAS 9 to help Latin America realise its potential as a food production powerhouse.

Potato and milk gene editing projects at the National Institute of Agricultural Technology (INTA) have made substantial strides. The researchers found that potato storage capacity at low temperatures can be enhanced as well as the number of antioxidants in the tuber. This disease is currently a significant problem for the Argentine industry. The president of INTA believes that the application of gene editing will increase agricultural and manufacturing productivity and resource efficiency.
The International Rice Research Institute (IRRI), based in the Philippines, has created gene-edited rice in partnership with the International Center of Tropical Agriculture (CIAT), situated in Palmira, Colombia, and has already gained authorizations (and is deemed conventional rice) from US and Colombian authorities. This rice that is resistant to bacterial blight disease was created using the CRISPR-Cas9 gene-editing technology. Regulatory agencies found that this new rice was not transgenic and could be governed as a traditional crop produced using traditional methods.
Researchers from the Federal University of Vicosa and the University of Sao Paulo in Brazil created a tomato variety based on a wild-type plant. Using CRISPR, they created a unique type that produces ten times the number of fruits. The fruits are also larger and have at least five times the antioxidant content of traditional ones.

Gene editing has the potential to encourage additional innovation in the field of agricultural biotechnology. This can lead to greater productivity and economic development, as well as a new tool in the arsenal for farmers battling climate change not only in Latin America but also in the rest of the world.

Middle East & African perspectives

Africa is plagued by food shortages as well as plant, animal, and human diseases. Some of these issues can be addressed by using gene editing technology. This technology has a wide range of applications in Africa, including crop and animal enhancement, illness diagnosis and treatment, boosting food shelf life, organoleptic qualities, and food safety.

Numerous scholars are looking into how genome editing might be used to improve and sustainably develop agricultural varieties in Africa. However, major funding and enabling laws are needed before genome editing products may be released.

Several products like Striga-resistant sorghum, MLN-resistant maize, and disease-resistant bananas are in the process and on their way to Africa. Because of the high frequency of tropical diseases and pests in the Middle East and Africa, gene editing is expected to assist human health and agricultural production. Furthermore, because of the gene drives and other prospective applications, CRISPR is perfect for treating a variety of genetic illnesses in Africa, such as sickle cell anaemia. Furthermore, due to high temperatures, the region recently saw a huge decline in crop yield. Because of this, plant breeders and scientists are attempting to develop new kinds of crops that are high yielding and resistant to biotic and abiotic problems like drought and insects.

The gene-editing technology is seen as a viable tool for treating many ailments, but in July 2022 Tel Aviv University researchers claim that it occasionally destroys genetic material, as seen in cancer.
Israeli researchers started to experiment with CRISPR gene editing therapy for SCID in September 2020, to restore a functional immune system in children with severe combined immune deficiency, or SCID. The researchers are excited to see the method through to the initial clinical trials.
CRISPR is especially well-suited for treating common hereditary disorders in Africa, such as sickle-cell anaemia (SCA), which had no cure until recently, when Ribeil and colleagues reported symptom remission in a patient using lentiviral gene therapy.
Gene editing techniques have been and continue to be applied in therapeutic research investigations with adult human cells in South Africa. However, the ethical issues surrounding somatic gene editing therapy are less contentious than those surrounding germline therapy. Various prestigious institutes such as the Massachusetts Institute of Technology, The Broad Institute among others have filed many patent applications in South Africa related to gene editing technology.
Editas Medicine is a genome editing firm that treats genetically specified disorders by modifying disease-causing genes. It also serves customers throughout the Middle East and Africa.

North America perspective

Because of pharmaceutical and biotech investment, improved healthcare infrastructure, increasing per capita income, and cutting-edge research facilities and institutions, North America dominated the global gene editing market.

Because of the increasing prevalence of rare diseases in the United States and Canada, North America accounted for 31% of the market in 2021 and is predicted to increase significantly in the following years. According to the National Institutes of Health, 25-30 million Americans are affected by 7,000 uncommon diseases (NIH). Demand for rare illness treatments is increasing as new gene editing methods and technology become available.

Because of increased government and private financing, North America is expected to take the lead in 2027.

Recently in November 2022, Scientists in the United States successfully reprogrammed cancer patients' immune systems to target the disease, paving the possibility for more personalised treatment. The experimental trial was modest, involving only 16 patients with unresponsive colon, breast, and lung malignancies. However, the researchers claim that their findings illustrate the safety and feasibility of adopting such technology and that they represent a "step ahead" in the development of customized cancer treatment.
Intellia Therapeutics is finishing the week on a high note, revealing positive results from two gene editing experiments. Both are in the early stages, but the business is already planning to enrol NTLA-2001, a transthyretin (ATTR) amyloidosis treatment, in what it thinks will be crucial research.

Even though there is no federal regulation dictating processes or limitations related to human genetic engineering acts of Congress in the United States have forbidden germline gene editing. There are federal restrictions on using public funds for research initiatives, tampering with human embryos, and conducting gene therapy clinical trials.

Canadian consumers have a more positive attitude toward gene editing technology than they do against GM technology. Trust in the Canadian food safety system, self-rated understanding of gene editing, and neophobia all testify to the necessity of consumers having access to scientific and credible information regarding developing food technologies. Canadians have low levels of scientific understanding and self-rated knowledge about gene editing technology, which limits their willingness to consume genetically engineered food products. As a result, there is a clear need for more scientific transparency to educate consumers about gene editing technologies.

Furthermore, CRISPR-edited crops are not considered GMOs in the United States, spurring agricultural firms to pursue commercialization. The leading companies in the gene editing market, including CRISPR Therapeutics, Bluebird bio, Intellia, and others are in the North American regions and extending their research capabilities in the same region.